genital%20herpes
GENITAL HERPES
Genital herpes is a recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV).
HSV-2 is usually the cause but HSV-1 may occur in up to 1/3 of new cases.
HSV-1 tends to cause fewer recurrences & milder disease than HSV-2.
The incubation period is 2 days-2 weeks after exposure.

Genital%20herpes Signs and Symptoms

Introduction

  • Recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV)
  • Typically occurs in adults, usually transmitted through sexual contact 
  • Incubation period is 2 days-2 weeks after exposure

Etiology

Herpes Simplex Virus (HSV)
  • HSV-1: Tends to cause fewer recurrences and milder disease than HSV-2
  • HSV-2: Usually the cause of genital herpes but HSV-1 may occur in up to 1/3 of new cases

Risk Factors

Risk Factors for Genital Herpes Simplex Virus Infection
  • Multiple sexual partners
  • Previous history of sexually transmitted infection (STI) including HIV
  • History of genital lesion in self or partner
  • Partner diagnosed with genital HSV infection
  • Early age of 1st sexual activity (≤17 years old)
  • Female gender
  • Low socioeconomic status; low level of education
  • Advancing age
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
16 Jan 2021
Diagnosis of heart diseases has abruptly and significantly decreased across the globe due to the coronavirus disease 2019 (COVID-19) pandemic, especially affecting poorer countries, reveals a study.
Roshini Claire Anthony, 01 Dec 2020

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.

Pearl Toh, Yesterday
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.